🏢 官网IRALKSCodex · 实盘不做把握 4/10
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:06:44 +6m44s·⚡ 决策 07-28 20:28:03 +1h21m·91.0 天前
Alkermes发布2026年二季度财报并将召开业绩电话会
本信号正文只是公司按排期发布二季度财报入口和电话会安排，未在可见正文中披露超预期收入、利润或指引上修幅度。
📄 原文ALKS↗ 原文
Alkermes plc Reports Second Quarter 2026 Financial Results
DUBLIN --(BUSINESS WIRE)--Jul. 28, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter…
不做 Alkermes（ALKS.US）
排期财报发布本身不构成交易催化；当前可见正文缺少相对一致预期的收入、利润或指引上修幅度，盘前价格也未显示重大重定价，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Alkermes官方发布二季度财报入口并宣布8:00 ET召开电话会，属于公司一手排期财报披露。市场反应:截至2026-07-28 12:26 UTC，ALKS.US报52.73美元，较前收-0.30%。
- Business Wire同步分发同一公司财报新闻稿，未单独提供可交易的业绩 surprise。
关键理由
- 本信号正文只是公司按排期发布二季度财报入口和电话会安排，未在可见正文中披露超预期收入、利润或指引上修幅度。
- Alkermes（ALKS.US）盘前报价52.73美元，较前收仅-0.30%，未显示市场正在对重大业绩惊喜重定价。
- 美股财报类事件默认需要相对一致预期的明确增量，本条缺少可量化 surprise，不能仅因官方财报发布而追多。
主要风险
- 详细财报或8:00 ET电话会若披露实质性上修/下修，需由新信号重新研判。
- ALKS近13周已明显上涨，若财报只是确认既有预期，盘中存在高开低走或回吐风险。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中Alkermes本次二季度业绩的超预期研报或旧闻扩散，未能支持追多。
检索:Alkermes Q2 2026 financial results guidance ALKS
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,979 字
DUBLIN
--(BUSINESS WIRE)--Jul. 28, 2026--
Alkermes plc
(Nasdaq: ALKS) today reported financial results for the quarter ended
June 30, 2026
. To view the detailed second quarter 2026
earnings press release
and presentation, please visit the company’s investor relations website at
https://investor.alkermes.com
.
Alkermes will host a conference call and webcast presentation at
8:00 a.m. ET
(
1:00 p.m. BST
) today, to discuss these financial results and expectations, and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at
https://investor.alkermes.com
. The conference call may be accessed by dialing +1 877 407 2988 for
U.S
. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.
About Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at
www.alkermes.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260727955871/en/
Alkermes Contacts:
For Investors: Sandy Coombs +1 781 609 6377
For Media: Katie Joyce +1 781 249 8927
Source: Alkermes plc
--(BUSINESS WIRE)--Jul. 28, 2026--
Alkermes plc
(Nasdaq: ALKS) today reported financial results for the quarter ended
June 30, 2026
. To view the detailed second quarter 2026
earnings press release
and presentation, please visit the company’s investor relations website at
https://investor.alkermes.com
.
Alkermes will host a conference call and webcast presentation at
8:00 a.m. ET
(
1:00 p.m. BST
) today, to discuss these financial results and expectations, and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at
https://investor.alkermes.com
. The conference call may be accessed by dialing +1 877 407 2988 for
U.S
. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.
About Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at
www.alkermes.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260727955871/en/
Alkermes Contacts:
For Investors: Sandy Coombs +1 781 609 6377
For Media: Katie Joyce +1 781 249 8927
Source: Alkermes plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。